Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
about
Management and Novel Adjuncts of Necrotizing Soft Tissue Infections.Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.Renal and hematologic side effects of long-term intravenous immunoglobulin therapy in patients with neurologic disorders.Intravenous immunoglobulin: pharmacological properties and use in polyneuropathies.Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study.Hypogammaglobulinemia and risk of severe infection in kidney transplant recipients.A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.The role of isoagglutinins in intravenous immunoglobulin-related hemolysis.Occurrence of acute renal failure on the same day as immune globulin product administrations during 2008 to 2014.Tolerability and safety of the intravenous immunoglobulin octagam(®) 10% in patients with immune thrombocytopenia: a post-authorisation safety analysis of two non-interventional phase IV trials.Severe intravenous immunoglobulin-induced hemolysis with pigment nephropathy managed with red cell exchange.Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study).Treatment of MuSK-Associated Myasthenia Gravis.Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases
P2860
Q30234954-416C2BE6-3DD0-4D56-AD0E-CB5F322CEDDEQ38304255-83F425D2-4B1E-44B6-8533-74FA83A66DBFQ38547186-E45708B2-BFD9-49F5-8B66-58C6EC351811Q38777462-C9C0B02E-A5E8-456F-8DC1-62FD0E411D85Q38900642-34D1688F-2018-42E9-AD43-0EAFC6BD5E2CQ39485911-14D7F3D6-D66C-45FD-89A8-450E9CF744E5Q39503723-332B1187-55F1-40EF-901F-396C472F6F95Q40133456-B3424206-B081-4508-A9E6-B7187195B1D4Q40736607-0A59617B-9273-46CE-8824-1B95762C91C4Q45069948-5BA709F2-9A27-4D60-A6B6-845657BFA129Q47819163-3DE47B3E-A89D-4994-AD40-B41DC11BEB11Q50438105-BEEC7613-DC2F-4737-8248-8868FF53DCD4Q52597380-22FED6C9-7DEB-4B9F-824D-7449C6E2CC82Q54379059-EBAF5439-09BA-469F-B20B-300C2858C63FQ57482179-C9C25E95-DE95-43BD-8DE1-6B5D5324318C
P2860
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@ast
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@en
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@en-gb
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@nl
type
label
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@ast
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@en
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@en-gb
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@nl
altLabel
Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk
@en
prefLabel
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@ast
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@en
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@en-gb
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@nl
P356
P1476
Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk
@en
P2093
Jacques Dantal
P304
P356
10.1159/000354893
P407
P577
2013-01-01T00:00:00Z